DDInter1731 DDInter1376
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Sunitinib {u} (Compound) resembles {v} (Compound) Metoclopramide
Sunitinib {u} (Compound) treats {v} (Disease) pancreatic cancer
Sunitinib {u} (Compound) binds {v} (Gene) SBK1
Sunitinib {u} (Compound) upregulates {v} (Gene) CRIP1
Sunitinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Sunitinib {u} (Compound) downregulates {v} (Gene) INTS3
Sunitinib {u} (Compound) causes {v} (Side Effect) Candida infection
Sunitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etravirine
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoprenaline
Sunitinib (Compound) resembles Metoclopramide (Compound)
Sunitinib (Compound) treats pancreatic cancer (Disease)
Sunitinib (Compound) binds SBK1 (Gene)
Sunitinib (Compound) upregulates CRIP1 (Gene)
Sunitinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Sunitinib (Compound) downregulates INTS3 (Gene)
Sunitinib (Compound) causes Candida infection (Side Effect)
Sunitinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Etravirine
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline